NBP

Business Context and Reporting Period

Company: I-Mab (Note: Input metadata referenced "Novabridge Biosciences," but the filing text identifies the registrant as I-Mab).
Filing Type: Form 6-K (Report of Foreign Private Issuer).
Reporting Period: Six months ended June 30, 2025.
Filing Date: October 6, 2025.
Business Overview: I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology agents. Following the divestiture of its Greater China assets in April 2024, the company operates primarily through its U.S. subsidiary. Its lead candidate is givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB for gastric cancer.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately $13.3 million (51.7%) year-over-year. R&D expenses dropped 63.9% and administrative expenses dropped 42.2%, driven by the divestiture of Greater China operations, lower headcount, and cost-sharing reimbursements from collaboration agreements.
• Discontinued Operations: The prior period (2024) included a $34.4 million gain from the sale of discontinued operations (Greater China assets), resulting in net income for that period. The current period has no discontinued operations activity.
• Investment Portfolio Shift: Short-term investments decreased significantly from $105.1 million to $0.2 million, while cash and cash equivalents increased from $68.3 million to $165.4 million, reflecting the maturity of investments and cash management strategies.
• Other Income: Other income, net, decreased from $5.5 million to $0.1 million, primarily due to the absence of fair value changes and extinguishment of put right liabilities in the current period, which were significant in the prior period.

Guidance, Outlook, and Risks

• Capital Raise: In August 2025, the company completed an underwritten offering of 33.3 million ADSs, raising net proceeds of approximately $61.2 million. These funds are intended to fund the randomized Phase 2 trial of givastomig and working capital.
• Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments (approx. $165.6 million) plus the recent $61.2 million proceeds will be sufficient to meet working capital and capital expenditure requirements for at least the next 12 months.
• Strategic Acquisitions: The company entered into an agreement to acquire 100% of Bridge Health Biotech Co., Ltd. for an upfront payment of $1.8 million plus non-contingent and milestone payments, expected to close in Q4 2025.
• Development Pipeline: The company is advancing givastomig (Phase 2) and ragistomig. Development of uliledlimab has been paused pending data from a partner in China.
• Risks: The company anticipates continued losses and will require additional capital for future development and commercialization. Risks include clinical trial outcomes, regulatory approvals, and the ability to raise further financing.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $165.4 million cash balance plus the $61.2 million recent raise against the projected burn rate for the givastomig Phase 2 trial.
• Bridge Health Acquisition: Confirm the closing of the Bridge Health acquisition and the total consideration obligations ($1.8M upfront + $1.2M non-contingent + up to $3.875M milestones).
• Discontinued Operations: Ensure financial analysis excludes the one-time $34.4 million gain from the 2024 divestiture when comparing operating performance.
• Collaboration Reimbursements: Review the sustainability of the $3.4 million R&D cost-sharing reimbursement from ABL Bio recognized in the current period.
• Legal Contingencies: Monitor the status of the settled arbitration regarding the Greater China divestiture and the ongoing trade secret litigation against Inhibrx, Inc.